Analyst Activity – Canaccord Genuity Reiterates Buy on Atara Biotherapeutics (NASDAQ:ATRA)

23

Analyst Ratings For Atara Biotherapeutics (NASDAQ:ATRA)

Today, Canaccord Genuity reiterated its Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) with a price target of $47.00.

There are 2 sell ratings, 3 buy ratings on the stock.

The current consensus rating on Atara Biotherapeutics (NASDAQ:ATRA) is Hold (Score: 2.20) with a consensus target price of $24.00 per share, a potential 26.98% upside.

Some recent analyst ratings include

  • 4/21/2017-Canaccord Genuity Reiterated Rating of Buy.
  • 9/15/2016-Goldman Sachs Group Inc was Downgraded by analysts at Goldman Sachs Group Inc from a “Neutral ” rating to a ” Sell” rating. They now have a $16.00 price target on the stock, up previously from $23.00 .
  • 7/9/2016-JMP Securities Reiterated Rating of Buy.
  • 12/15/2015-William Blair Reiterated Rating of Buy.

Dividend information for Atara Biotherapeutics (NASDAQ:ATRA)

.
Recent Insider Trading Activity For Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics (NASDAQ:ATRA) has insider ownership of 16.10% and institutional ownership of 77.48%.

  • On 4/17/2017 Christopher Haqq, EVP, sold 6,000 with an average share price of $17.28 per share and the total transaction amounting to $103,680.00. View SEC Filing
  • On 4/11/2017 Isaac E Ciechanover, CEO, sold 7,200 with an average share price of $17.03 per share and the total transaction amounting to $122,616.00. View SEC Filing
  • On 3/28/2017 Isaac E Ciechanover, CEO, sold 16,000 with an average share price of $20.06 per share and the total transaction amounting to $320,960.00. View SEC Filing
  • On 3/23/2017 John Mcgrath, CFO, sold 14,000 with an average share price of $20.65 per share and the total transaction amounting to $289,100.00. View SEC Filing
  • On 3/17/2017 Isaac E Ciechanover, CEO, sold 30,800 with an average share price of $19.38 per share and the total transaction amounting to $596,904.00. View SEC Filing
  • On 3/10/2017 Gad Soffer, EVP, sold 2,500 with an average share price of $20.00 per share and the total transaction amounting to $50,000.00. View SEC Filing
  • On 3/10/2017 John Mcgrath, CFO, sold 24,000 with an average share price of $20.00 per share and the total transaction amounting to $480,000.00. View SEC Filing

About Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company’s product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company’s T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Recent Trading Activity for Atara Biotherapeutics (NASDAQ:ATRA)
Shares of Atara Biotherapeutics closed the previous trading session at 16.52 down -2.38 -12.57% with 172,985 shares trading hands.